CC Bio is at the forefront of precision healthcare, utilizing synthetic biology to revolutionize the diagnosis and treatment of microbiome-based diseases. The company focuses on engineering and editing the microbiome with high precision, aiming to eliminate such diseases in a targeted and preventive manner. By harmonizing the interactions between eukaryotic and microbial cells, CC Bio seeks to empower consumers by moving beyond traditional antibiotic treatments and addressing the holistic needs of patients. This innovative approach emphasizes the importance of understanding the microbiome's role in human health and aims to restore balance within it.

To support its mission, CC Bio has developed a proprietary drug discovery platform named Zeus. This platform is designed to evaluate and optimize thousands of potential therapeutics that can enhance microbial ecology effectively. The most promising candidates identified through this rigorous discovery process are currently advancing through preclinical development. By leveraging cutting-edge synthetic biology techniques, CC Bio is committed to pioneering new treatments that address the complexities of microbiome-related health issues, ultimately contributing to a more personalized and effective healthcare landscape.

United Kingdom

Synthetic biology is changing the way we think about diagnosing and treating microbiome-based diseases.

At CC Bio, we harness the power of synthetic biology to engineer and edit the microbiome with surgical precision. Our goal is to eliminate microbiome-based disease in a potent, specific and prophylactic fashion, harmonising the relationship between eukaryotic and microbial cells.

By considering the lifestyle needs of our patients, and understanding each microbiome-based disease holistically, we are elevating this fundamental aspect of human health out of the antibiotic era, putting power back in the hands of the consumer.

CC Bio

Company Details